Seizures Pipeline H2 2016 Market Review Research Report

Sep 01, 2016, 06:00 ET from ReportsnReports

PUNE, India, September 1, 2016 /PRNewswire/ -- adds "Seizures - Pipeline Review, H2 2016" market research report providing comprehensive information on the seizure therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Seizures targeted therapeutics development and features dormant and discontinued projects.

Complete report on H2 2016 pipeline review of Seizures with 51 market data tables and 15 figures, spread across 214 pages is available at .

Seizures are symptoms of a brain problem. They happen due to sudden, abnormal electrical activity in the brain. Symptoms include dizziness, changes in vision, feeling sick to stomach, anxiousness and uncontrollable muscle spasms.

Companies discussed in this Seizures Pipeline Review, H2 2016 report include Adamas Pharmaceuticals, Inc., Advicenne, Alexza Pharmaceuticals, Inc., Biscayne Pharmaceuticals, Inc., Catalyst Pharmaceuticals, Inc., Eisai Co., Ltd., GW Pharmaceuticals Plc, INSYS Therapeutics, Inc., Lotus Pharmaceutical Co., Ltd., Marinus Pharmaceuticals, Inc., Neurelis, Inc., Novartis AG, OPKO Health, Inc., Pfizer Inc., PTC Therapeutics, Inc., Sage Therapeutics, Inc., SciFluor Life Sciences, LLC, Shire Plc, SK Biopharmaceuticals Co., Ltd., Suda Ltd, Turing Pharmaceuticals AG, UCB S.A., Ultragenyx Pharmaceutical Inc., Upsher-Smith Laboratories, Inc., Xenon Pharmaceuticals Inc., XERIS Pharmaceuticals, Inc., Zogenix, Inc. and Zynerba Pharmaceuticals, Inc. Drug Profiles mentioned in this research report are ADS-4101, ADV-6208, ADV-6770, alprazolam, AMPX-0079, ataluren, BIS-001, brivaracetam, cannabidiol, cannabidiol, CCG-63802, CHEC-9, clobazam, CNSA-004, CPP-115, CUR-1916, diazepam, everolimus, fenfluramine hydrochloride, fosphenytoin sodium, ganaxolone, lacosamide, levetiracetam, levetiracetam ER, lorazepam, LSPGR-1, magnesium valproate hydrate, MB-003, midazolam hydrochloride, Oligonucleotide for Dravet Syndrome, perampanel, pregabalin, SAGE-217, SAGE-689, selurampanel, sepranolone, SF-0034, Small Molecule for Stroke and Epilepsy, Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders, Small Molecule to Block Nav1.6 for Dravet Syndrome, Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus, Small Molecules for Seizure Disorders, Small Molecules for Seizures, TG-4155, TRP-001, TUR-004, TUR-005, UX-007, YKP-3089 and ZYN-002.

Order a copy of H2 2016 seizures pipeline market research report @ .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Furthermore, this report also reviews key players involved in Seizures targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Seizures and reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Seizures therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Seizures.

Another newly published market research report titled on Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Companies discussed in this research are Almirall, S.A., Anacor Pharmaceuticals, Inc., Arno Therapeutics, Inc., Blueberry Therapeutics Ltd, Crescita Therapeutics Inc., Eisai Co., Ltd., Helix BioMedix, Inc., Hexima Limited, Meiji Seika Pharma Co., Ltd., Moberg Pharma AB, NAL Pharmaceuticals Ltd., Nihon Nohyaku Co., Ltd., Novabiotics Limited, Novan, Inc. and Viamet Pharmaceuticals, Inc. Onychomycosis (Tinea Unguium) Pipeline market research report of 81 pages is available at .

Explore more reports on Pharmaceuticals.

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441

Connect With Us on:



Twitter:  https: //

G+ / Google Plus:


SOURCE ReportsnReports